Nurix Therapeutics, Inc. (NRIX) - Stock Analysis
Last updated: Jun 28, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong near-term catalyst and momentum setup: stock rose about 42% over 21 trading days, supported by Roche collaboration worth up to $2.3B with $700M upfront and positive NX-5948 CLL/SLL data including 92.9% ORR in a second-line group.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Heavy Cash Burn ⢠Wide Losses NRIX has a strong balance sheet and ample net cash, but worsening liquidity, deep operating losses, and heavy cash burn show it remains far from profitability despite high gross margins.
Price Behavior
Key Price Behavior Insights: ⢠Higher-highs trend ⢠Key support hold ⢠Fast rally risk Support Level: $17.00-$17.50 Resistance Level: $22.90 NRIX has shifted from a base into a strong short-term uptrend over the last month, with higher highs/lows and a breakout above the $17.00-$17.50 support zone, though the fast rally now raises near-term pullback risk if momentum stalls.
Sentiment & News
Key News Insights: ⢠Roche validation ⢠Clinical momentum ⢠Extended runway Nurix's Roche partnership for bexobrutideg, backed by $700M upfront plus up to $2.3B in milestones and strong Phase 1 data, materially boosts validation, funding visibility, and near-term investor sentiment.
AI Summary
Nurix has moved from a speculative early-stage biotech to a partner-validated platform after the Roche deal, but the investment now hinges on NX-5948 delivering durable, registrational-quality data fast enough to justify the higher valuation while the company continues burning cash.
Description
Nurix Therapeutics is a biopharmaceutical company that discovers and develops small-molecule treatments for oncology and immune disorders, with an emphasis on orally administered BTK degraders and CBLâB modulators. Its pipeline includes agents for relapsed or refractory Bâcell malignancies, therapies to support adoptive Tâcell approaches, and a cell therapy candidate in Phase 1 for gynecologic cancers. The company collaborates with Gilead and Sanofi, was incorporated in 2009, and is headquartered in San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 2 | Jul 9 | NRIX | Nurix Therapeutics, Inc. | Strong near-term catalyst and momentum setup: stock rose about 42% over 21 trading days, supported by Roche collaboration worth up to $2.3B with $700M upfront and positive NX-5948 CLL/SLL data including 92.9% ORR in a second-line group. | Active | +0.0% |